AMSBIO has expanded its portfolio of stable cell lines. The new cell lines express endogenous or recombinant proteins and are available in a ready-to-use format to facilitate your research efforts.
Using AMSBIO stable cell lines not only provides an optimised solution for manufacture of therapeutic and diagnostic protein, but also for applications in drug screening, pharmacological research and toxicological studies.
The extensive portfolio of ready-to-use stable cell lines available from AMSBIO includes: Receptors (RAR a, IGF1 Receptor, Motilin Receptor MLNR...); Ion channels (CFTR, Nav1.7, Kv1.5…); Cell signalling (Notch, JNK, NF-?B, ERK…); Phosphodiesterases (aequorin, CNGA2, PDE1B…); Stem cell related (LGR5, OCT4, LIN28); Fluorescent (GFP, RFP, CFP, YFP); TetR ; Luciferase; CRE recombinase/reporter ; p53 and DNA repair gene knock-down cell lines (PARP1, MUTYH, MSH2, MLH1, XRCC6, BRCA1, NBS1…).
For further information, visit www.amsbio.com
